Loading...
Drug Pricing Investigation: Teva--Copaxone
House Committee on Oversight and Reform
House Committee on Oversight and Reform
Citations
Altmetric:
Abstract
The House Committee on Oversight and Reform issued a Staff Report on the pricing practices of Teva Pharmaceuticals concerning the drug Copaxone. The report includes recommendations.
Date
2020-09-30
Document Type
House Staff Report
Serial Number
Document Length
55 pages
Congress
116
Relation
DOI
Keywords
Staff Reports, House
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Cited Hearings
• Senate Committee on Finance, hearing on "Drug Pricing in America: A Prescription for Change, Part I," 116th Cong., S.Hrg. 116-267, (2019, January 29)
• Senate Committee on Finance, hearing on "Drug Pricing in America: A Prescription for Change, Part II," 116th Cong., S.Hrg. 116-39, (2019, February 26)
• Senate Committee on Finance, hearing on "Drug Pricing in America: A Prescription for Change, Part III," 116th Cong., S.Hrg. 116-415, (2019, April 9)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part II)," 116th Cong., H.Hrg. 116-123, (2020, October 1)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., H.Hrg. 117-22, (2021, May 18)
• Senate Committee on Finance, hearing on "Drug Pricing in America: A Prescription for Change, Part II," 116th Cong., S.Hrg. 116-39, (2019, February 26)
• Senate Committee on Finance, hearing on "Drug Pricing in America: A Prescription for Change, Part III," 116th Cong., S.Hrg. 116-415, (2019, April 9)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part II)," 116th Cong., H.Hrg. 116-123, (2020, October 1)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., H.Hrg. 117-22, (2021, May 18)